Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Seriousness of Target Diseases, Efficacy Became Key in Sakigake Designation: MHLW Official
January 20, 2016
- Drug Makers Told to Check Conformity of Manufacturing Process with Approved Methods
January 20, 2016
- PAFSC’s 2nd Committee to Review Novartis’s Melanoma Drugs on Feb. 1
January 20, 2016
- “Huge Seller” Re-Pricing to Hit Sovaldi, Harvoni, Avastin, Plavix
January 20, 2016
- Discussions on Market Price Survey for 2017 Revision Likely to Begin in March, Conclusion Expected in June
January 19, 2016
- Abe Vows to Work All-Out to Supervise Drug Manufacturers after Kaketsuken Oversight
January 19, 2016
- ICH-S9 Guideline to Apply to Non-Clinical Studies for “Serious Malignancies”
January 19, 2016
- New ICH Trial Guidelines to Embrace “Pooled Populations,” but PMDA Unlikely to Accept Zero Japanese
January 18, 2016
- MHLW Taskforce on Vaccines, Blood Products Kicks Off Discussions
January 15, 2016
- Research-Driven Makers Should Find Another Biz Model If They Can’t Innovate: Top Bureaucrat
January 15, 2016
- Fulminant Hepatitis to Be Added to List of Significant Adverse Reactions to Amlodipine Products
January 14, 2016
- AMED, US NIH Ink Memorandum of Cooperation for Orphan Diseases, Cancer
January 13, 2016
- Kaketsuken Ordered Record 110-Day Suspension, Shiozaki Says He Won’t Allow It to Remain As-Is
January 12, 2016
- Re-Pricing Rule for “Huge-Seller” Drugs Necessary Compromise to Protect Universal Healthcare While Promoting Innovation: Health Minister
January 12, 2016
- Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
- Careful Administration Re-stressed for Inavir, Relenza in Dairy-Sensitive Patients: Safety Bulletin
January 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for December 2015
January 8, 2016
- Shipment of Some Lots of Kaketsuken’s Kenketsu Globulin OK’ed
January 7, 2016
- Health Policy Bureau’s FY2016 Draft Budget Earmarks 5.7 Billion Yen to Promote Clinical Research
January 5, 2016
- Health Service Bureau Increases Budgets for Measures against Hepatitis, Infectious Diseases: FY2016 Draft Budget
January 5, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…